Bone Total Debt To Capitalization from 2010 to 2025

BBLGW Stock  USD 54.50  2.46  4.73%   
Bone Biologics Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization is likely to outpace its year average in 2025. During the period from 2010 to 2025, Bone Biologics Total Debt To Capitalization regression line of quarterly data had mean square error of  580.60 and geometric mean of  7.31. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
(6.84)
Current Value
(6.50)
Quarterly Volatility
23.49272303
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 11.4 M, Ebitda of 453.2 K or Total Operating Expenses of 11.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.39. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
  
Check out the analysis of Bone Biologics Correlation against competitors.

Latest Bone Biologics' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Bone Biologics Corp over the last few years. It is Bone Biologics' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Pretty Stable
   Total Debt To Capitalization   
       Timeline  

Bone Total Debt To Capitalization Regression Statistics

Arithmetic Mean(1.86)
Geometric Mean7.31
Coefficient Of Variation(1,260)
Mean Deviation12.73
Median(5.95)
Standard Deviation23.49
Sample Variance551.91
Range117
R-Value(0.13)
Mean Square Error580.60
R-Squared0.02
Significance0.62
Slope(0.66)
Total Sum of Squares8,279

Bone Total Debt To Capitalization History

2025 -6.5
2024 -6.84
2020 -5.95
2019 -20.67
2018 22.4
2017 -49.54
2016 67.95

About Bone Biologics Financial Statements

Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Debt To Capitalization(6.84)(6.50)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.